JP2025522146A - 不眠症を治療するための医薬組成物および方法 - Google Patents

不眠症を治療するための医薬組成物および方法 Download PDF

Info

Publication number
JP2025522146A
JP2025522146A JP2025524504A JP2025524504A JP2025522146A JP 2025522146 A JP2025522146 A JP 2025522146A JP 2025524504 A JP2025524504 A JP 2025524504A JP 2025524504 A JP2025524504 A JP 2025524504A JP 2025522146 A JP2025522146 A JP 2025522146A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
alprazolam
ebastine
present
amount ranging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025524504A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024010592A5 (https=
JP2025522146A5 (https=
Inventor
ワン，ジアンミン
ツイ，ゴーピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2025522146A publication Critical patent/JP2025522146A/ja
Publication of JPWO2024010592A5 publication Critical patent/JPWO2024010592A5/ja
Publication of JP2025522146A5 publication Critical patent/JP2025522146A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2025524504A 2022-07-08 2022-07-08 不眠症を治療するための医薬組成物および方法 Pending JP2025522146A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2022/036579 WO2024010592A1 (en) 2022-07-08 2022-07-08 Pharmaceutical compositions and methods for treating insomnia

Publications (3)

Publication Number Publication Date
JP2025522146A true JP2025522146A (ja) 2025-07-10
JPWO2024010592A5 JPWO2024010592A5 (https=) 2025-07-17
JP2025522146A5 JP2025522146A5 (https=) 2025-07-17

Family

ID=89453886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025524504A Pending JP2025522146A (ja) 2022-07-08 2022-07-08 不眠症を治療するための医薬組成物および方法

Country Status (7)

Country Link
US (1) US20250205218A1 (https=)
EP (1) EP4551220A1 (https=)
JP (1) JP2025522146A (https=)
CN (1) CN119255803A (https=)
AU (1) AU2022468585A1 (https=)
CA (1) CA3261198A1 (https=)
WO (1) WO2024010592A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370198B2 (en) 2022-07-08 2025-07-29 La Pharmatech Inc Pharmaceutical compositions and methods for treating psychiatric disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10898493B2 (en) * 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
WO2021005189A1 (fr) * 2019-07-09 2021-01-14 Universite De Bretagne Occidentale (Ubo) Nouveaux composés inhibiteurs de la pfar

Also Published As

Publication number Publication date
EP4551220A1 (en) 2025-05-14
US20250205218A1 (en) 2025-06-26
WO2024010592A1 (en) 2024-01-11
AU2022468585A1 (en) 2025-02-20
CA3261198A1 (en) 2024-01-11
CN119255803A (zh) 2025-01-03

Similar Documents

Publication Publication Date Title
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
US11690849B2 (en) Method of treating dementia
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
US20200101067A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
TW202339764A (zh) 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
US20210069209A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
KR20150135339A (ko) 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도
WO2021242297A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
US20250205218A1 (en) Pharmaceutical compositions and methods for treating insomnia
US11744833B2 (en) Pharmaceutical compositions and methods for treatment of insomnia
JP2025526852A (ja) 不眠症の治療のための新規医薬組成物及び方法
JP2025518975A (ja) 精神疾患の治療のための新規医薬組成物及び方法
CN1327843C (zh) 氟马西尼在用于可卡因依赖治疗药物制备中的应用
US11628174B1 (en) Pharmaceutical compositions and methods for treating insomnia
CN1268332C (zh) 用于治疗膀胱疾病的k－阿片受体激动剂
US10071077B2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
US12370198B2 (en) Pharmaceutical compositions and methods for treating psychiatric disorders
HK40119515A (zh) 用於治疗失眠症的新型药物组合物和方法
CN102470125A (zh) 苄达明在治疗p40-依赖性疾病中的用途
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
Yadav et al. AYURVEDIC MANAGEMENT OF VICHARCHIKA (ECZEMA): A CASE STUDY
WO2026080932A2 (en) Compounds, compositions, and methods of use thereof
Yildiz Non-Allergic Rhinitis
CN115364085A (zh) 一种用于缓解早泄的组合片
HK1064036B (en) Kapp-opiate agonists for the treatment of bladder dieseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250708